GLP-1 Agonists and Muscle Loss: What the Latest Data Actually Shows

**A 2026 retrospective study of 7,965 patients found tirzepatide causes 2x more lean mass loss than semaglutide at 12 months. But the full picture is more nuanced than the headline.**

The headline

GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — are the most prescribed weight loss medications in history. In 2025, 1 in 8 US adults took a GLP-1 drug. The market hit $52.6 billion.

They work. Total body weight loss of 10-15% is standard. Tirzepatide achieves 15%+ at 12 months.

The problem: not all weight lost is fat. Some of it is lean body mass — muscle, bone, organ tissue. And a 2026 study using real-world data from 29 million patient records found the lean mass loss is more significant than previously understood, especially with tirzepatide.

The 2026 study — what it actually found

Murugadoss et al. analyzed 7,965 patients (6,196 semaglutide, 1,769 tirzepatide) from the nSights Federated EHR Network — the largest real-world body composition comparison to date.

**Lean body mass (LBM) loss at 12 months:**

| Drug | LBM Loss | Total Weight Loss | LBM as % of Total Loss | |------|----------|-------------------|------------------------| | Semaglutide | −2.3 kg (3.6%) | −9.7% | ~37% | | Tirzepatide | −3.3 kg (5.6%) | −15.2% | ~37% |

The proportion is similar — roughly 37% of total weight loss is lean mass for both drugs. But because tirzepatide drives more total weight loss, the absolute lean mass loss is significantly higher.

**The dose-response finding:** - Semaglutide: each 1 mg increase → 1.9% additional LBM loss - Tirzepatide: each 1 mg increase → 0.45% additional LBM loss - Extended tirzepatide use (7+ prescriptions): LBM loss reaches −7.2%

**The metabotype analysis** is the most interesting part. The researchers defined two phenotypes:

• **Prime GLP-1 Metabotype** — ≥10% total weight loss with <5% LBM loss (favorable outcome)
• **Depletive GLP-1 Metabotype** — >20% total weight loss with ≥5% LBM loss (concerning)

1. % of semaglutide patients and 11.8% of tirzepatide patients hit the "Prime" profile. But 10.3% of tirzepatide patients fell into the "Depletive" category, compared to 6.7% for semaglutide (p<0.001).

But context matters

Before the headlines write themselves, some important caveats:

**1. Most patients do fine.** ~65.7% of both groups had less than 5% LBM loss. For the majority, lean mass preservation is adequate during GLP-1 treatment.

**2. The study used real-world data, not controlled trials.** ~85% of body composition measurements came from BIA (bioelectrical impedance analysis), which is less accurate than DEXA. The researchers used LLM-based extraction from clinical notes — innovative but not gold standard.

**3. The study is a preprint.** It has not been peer-reviewed. The authors explicitly state it "should not guide clinical practice."

**4. Some muscle loss during weight loss is normal.** Any caloric deficit catabolizes some lean tissue. The question is whether GLP-1 agonists cause disproportionate muscle loss compared to diet alone — and the evidence there is mixed. Rossi et al. (2025) found that oral semaglutide preserved fat-free mass in type 2 diabetes patients over 26 weeks.

**5. Resistance exercise is the countermeasure.** The LEAN trial (NCT06885736) is actively recruiting to test whether resistance training + protein supplementation can preserve muscle during GLP-1 treatment. This is the practical answer, not a different drug.

What this means for the peptide research space

This is where it gets relevant for the EVOLVŌ audience:

• **The muscle preservation concern is real** — it's not anti-GLP-1 fearmongering. The data shows a subset of patients lose significant lean mass.
• **This creates demand for adjunct research** — compounds that support muscle preservation during caloric deficit are increasingly relevant.
• **BPC-157 and TB-500 are positioned for this conversation** — their tissue repair mechanisms are complementary to GLP-1 weight management, though no direct combination studies exist.
• **Quality matters more than ever** — if someone is researching adjunct compounds while on GLP-1 therapy, they need verified, COA-backed products. Not mystery vials.

The practical takeaway

If you're researching GLP-1 agonists and body composition:

1. **Track body composition, not just scale weight.** BIA scales are imperfect but better than nothing. DEXA is gold standard.
2. **Resistance training is non-negotiable.** The LEAN trial is testing this formally, but the evidence for exercise preserving muscle during caloric deficit is already strong.
3. **Protein intake matters.** 1.2-1.6 g/kg/day during GLP-1 treatment is the emerging recommendation.
4. **Longer tirzepatide courses = more lean loss.** The data shows escalating LBM loss with more prescriptions. Shorter courses with maintenance strategies may be preferable.
5. **Monitor, don't assume.** Individual response varies enormously. The study found "marked within-dose-tier heterogeneity" — same dose, very different outcomes.

What we're watching

• **LEAN trial results** (NCT06885736) — resistance exercise + protein during GLP-1. Expected 2027.
• **Next-generation GLP-1 agonists** with muscle-sparing properties. Several in Phase II.
• **Oral semaglutide** — Wegovy pill launched in 2026 at $149-299/month, significantly cheaper than injectable. Will expand the patient population massively.
• **Retatrutide** — triple agonist (GLP-1 + GIP + glucagon) showing 24% weight loss in Phase II. The muscle preservation question will be even more urgent at that magnitude.

*This article is for educational and research purposes only. GLP-1 agonists are prescription medications. Peptides discussed are sold for research use. Not medical advice. No therapeutic claims are made.*